Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials.
Stavraka C. et al, (2014), Cancer, 120, 262 - 270
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): Preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study
Corrie PG. et al, (2014), The Lancet Oncology, 15, 620 - 630
Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer
Blagden S. et al, (2014), EUROPEAN JOURNAL OF CANCER, 50, 7 - 7
An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials.
Pinato DJ. et al, (2014), PLoS One, 9
Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: Current and future perspectives in adult and paediatric disease
Eyre TA. et al, (2014), European Journal of Haematology
Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect
Eyre TA. et al, (2014), International Journal of Hematology, 1 - 3
Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma.
Collins GP. et al, (2014), Br J Haematol, 164, 39 - 52
Long-term outcomes of autologous stem cell transplantation for peripheral T-cell lymphomas across the Thames Valley (1997-2012)
Sims MC. et al, (2014), British Journal of Haematology
Modification of British committee for standards in haematology diagnostic criteria for essential thrombocythaemia
Harrison CN. et al, (2014), British Journal of Haematology, 167, 421 - 423
NUC-1031: A novel ProTide that overcomes the key cancer resistance mechanisms associated with poor survival
Ghazaly EA. et al, (2014), CANCER RESEARCH, 74
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
Greenhalf W. et al, (2014), J Natl Cancer Inst, 106
Partial engraftment following plerixafor rescue after failed sibling donor peripheral blood stem cell harvest
Eyre TA. et al, (2014), Transfusion, 54, 1231 - 1234
T-cell/histiocyte-rich large B-cell lymphoma - transformation of Nodular lymphocyte predominant Hodgkin lymphoma in the bone marrow
Eyre TA. et al, (2014), European Journal of Haematology, 92, 550 - 551
The mRNA-binding protein LARP1 is a pro-survival factor that promotes tumourigenicity and chemotherapy resistance in ovarian cancer
Hopkins TG. et al, (2014), EUROPEAN JOURNAL OF CANCER, 50, S26 - S26
Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies
Eyre TA. et al, (2014), British Journal of Haematology
Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study.
Lorigan P. et al, (2014), Br J Dermatol, 170, 87 - 95
Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
Reilly JT. et al, (2014), British Journal of Haematology, 167, 418 - 420
Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study.
Fotopoulou C. et al, (2014), Ann Oncol, 25, 160 - 165
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.
Horsley L. et al, (2013), Cancer Chemother Pharmacol, 72, 1343 - 1352
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours
Horsley L. et al, (2013), Cancer Chemotherapy and Pharmacology, 72, 1343 - 1352